Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Indoor Residual Spray for Dengue Vector Control
NCT07838701Completed
- Sponsor
- Pak Emirates Military Hospital
- Start
- May 2024
- Primary completion
- May 2025
- Countries
- 1
01
Overview
Open-label trial (2 arms), sponsored by Pak Emirates Military Hospital. Primary endpoints: Adverse side effects at 3 months, House Index at 3 months and 1 more. Started May 2024; status: completed.
Beyond the preview
Go deeper on NCT07838701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07838701.